natgillin/translations-raw huggingface dataset:
1.25 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.
1,25 ml/100 kg tjelesne mase) u kombinaciji s antibiotskom terapijom ili peroralnom rehidracijskom terapijom, kako je odgovarajuće.
1.25, 2.5, 5, 10 or 15 ml of solution in a vial (Type I glass) with a stopper (chlorobutyl rubber).
1,25; 2,5; 5; 10 ili 15 ml otopine u bočici (staklo tipa I) s čepom (bromobutilna guma).
1.28 ml (Fill: 1.71 ml)
1,28 ml (Punjenje: 1,71 ml)
1.29
paritaprevir
1.3 g/m2/day.
1,3 g/m2/dan cisteamina.
1.3 mg/kg once daily
1,3 mg/kg jedanput na dan
1.3 mg/m2 once per week
1,3 mg/m jedanput tjedno
1.3 microgram/kg/min infusion (180/1.3).
1,3 mikrograma/kg/min (180/1,3).
1.3 – Not Reached
1,3 – Nije dostignuto
1.3% (95% CI: -2.5% to 5.1%)
1,3% (95% CI: -2,5% to 5,1%)
1.30 g/ m2/day.
1,30 g/ m2/dan.
1.30 mL/min to 1.55 mL/min.
1,30 mL/min do 1,55 mL/min.
1.31)
Europsko
1.33 ml/10 kg bodyweight) on the first day.
1,33 ml/10 kg tjelesne mase), prvi dan.
1.34 to 1.81
1,34 do 1,81
1.4. Gadolinium-enhancing lesions at baseline: no data.
Lezije koje se imbibiraju gadolinijem na početku liječenja: nema podataka.
1.40 the spine (n=154).
1.40 za kralježnicu (n=154).
1.41 (1.11, 1.79), P=0.0047
Vareniklin naspram bupropiona
1.41 to 12.7) ng/ml, respectively).
1,41 do 12,7) ng/ml).
1.43 (1.22-1.68)
INHIBITORI HMG CoA REDUKTAZE
1.45 to 2.19
1,45 do 2,19
1.46
atazanaviru.
1.48, 4.69
Odgovor CTN-a
1.48f (0.79, 2.75)
1,48f (0,79; 2,75)
1.5 % , respectively).
Pretrage
1.5 m vs 5.5 m
1,5 m vs 5,5 m
1.5 mcg/kg/week
1,5 µg/kg na tjedan
1.5 mg methylhydroxybenzoate/ml
1,5 mg metilhidroksibenzoata/ml
1.5 mg tablet: yellow-orange, round, biconvex tablets of 6 mm, marked with the Bayer cross on one side and 1.5 and an “R” on the other side.
1,5 mg tableta: žutonarančaste, okrugle, bikonveksne tablete od 6 mm, označene Bayerovim križem s jedne strane te brojem 1.5 i slovom “R” s druge strane.
1.5 mg/kg body weight subcutaneously once daily
1,5 mg/kg tjelesne težine supkutano jedanput na dan
1.5 mg/kg bw subcutaneously once daily
1,5 mg/kg TT supkutano jedan puta na dan
1.5 mg/kg bw subcutaneously once daily
1,5 mg/kg TT supkutano jedanput na dan
1.5 ml (30 mg) twice daily
1,5 ml (30 mg) dvaput na dan
1.5 ml liquid in clear borosilicate Type I glass vial, closed with a chlorobutyl elastomeric lyophilisation stopper, and sealed with an aluminium crimp seal having a plastic flip-off button.
1,5 ml tekućine u prozirnoj bočici od borosilikatnog stakla tipa I, zatvorena klorobutilnim elastomernim liofilizacijskim čepom te zapečaćena aluminijskim prstenom s plastičnom „flip-off” kapicom.
1.5 mL medium chain triglycerides
1,5 ml triglicerida srednje duljine lanca
1.5 ml of oral suspension in a pre-filled oral applicator (type I glass) with a plunger stopper (rubber butyl) and a protective tip cap (rubber butyl) in pack sizes of 1, 5, 10 or 25.
1,5 ml oralne suspenzije u napunjenom oralnom aplikatoru (staklo tipa I) sa čepom klipa (butil guma) i zaštitnim zatvaračem vrha (butil guma), u veličinama pakiranja od 1, 5, 10 ili 25.
1.5 ml of oral suspension in a squeezable tube (polyethylene) fitted with a membrane and a tube cap (polypropylene) in pack sizes of 1, 10 or 50.
1,5 ml oralne suspenzije u tubi za istiskivanje (polietilen) sa membranom na vrhu i zatvaračem tube (polipropilen) u veličini pakiranja od 1, 10 ili 50.
1.5 ml of solution in a cartridge (colourless type I glass) with plunger and a blue ring on one side (siliconised bromobutyl), a disc (bromobutyl) and a cap (aluminium) on the other side.
1,5 ml otopine u ulošku (bezbojno staklo tip I) s klipom i plavim prstenom na jednoj strani (silikonizirani bromobutil), te diskom (bromobutil) i zatvaračem (aluminij) na drugoj strani.
1.5 ml/100 kg body weight).
1,5 ml/100 kg tjelesne mase).
1.5 x 100 mg† twice daily
1,5 x 100 mg† dvaput na dan
1.5 x 100 mg‡ twice daily
1,5 x 100 mg‡ dvaput na dan
1.5 x 109/l, the platelet count is more than or equal to 100 x 109/l, and the haemoglobin level is more than or equal to 9 g/dl (after transfusion if necessary).
≥100 x 109/l, a razina hemoglobina ≥9 g/dl (nakon transfuzije, ukoliko je potrebna).
1.5 x 109/l, the platelet count is more than or equal to 100 x 109/l, and the haemoglobin level is more than or equal to 9 g/dl (after transfusion if necessary).
100 x 109/1, a razina hemoglobina  9 g/d1 (nakon transfuzije, ukoliko je potrebna).
1.5 x 109/l, the platelet count is more than or equal to 100 x 109/l, and the haemoglobin level is more than or equal to 9 g/dl (after transfusion if necessary).
100 x 109/l, a razina hemoglobina  9 g/dl (nakon transfuzije, ukoliko je potrebna).
1.5 x 109/l, the platelet count is more than or equal to 100 x 109/l, and the haemoglobin level is more than or equal to 9g/dl (after transfusion if necessary).
100 x 109/1, a razina hemoglobina  9 g/d1 (nakon transfuzije, ukoliko je potrebna).
1.5 – 3.8 RP*
1,5 – 3,8 RP
1.5 C) may occur for 1 to 2 days.
1.5°C) može trajati 1 do 2 dana.
1.5% (95% CI: -1.8% to 4.8%)
1,5% (95% CI: -1,8% do 4,8%)
1.5% (95% CI: -2.2% to 5.2%)
1,5% (95% CI: -2,2% do 5,2%)
1.5-2.5 hours).
1,5 - 2,5 sata).
1.5-3.8 RP
1,5-3,8 RP
1.5. Treatment with Enbrel 25 mg resulted in substantial improvement at 12 months, with about 44% of patients achieving a normal HAQ score (less than 0.5).
Liječenje dozom Enbrela od 25 mg rezultiralo je znatnim poboljšanjem nakon 12 mjeseci s oko 44% bolesnika koji su dostigli normalnu ocjenu na upitniku HAQ (manje od 0,5).
1.50 to 1.78
1,50 do 1,78
1.51 (1.19, 1.93), P=0.0008
1,52 (1,23, 1,89), P=0,0001 1.51 (1,19, 1,93), P=0,0008 a
1.52
(95% C.I.)
1.52
paritaprevir
1.52 (1.23, 1.89), P=0.0001
1,49 (1,20, 1,85) P=0,0003 1.41 (1,11, 1,79), P=0,0047
1.55 (1.05, 2.06) c
1,55 (1,05; 2,06) c
1.5xULN < transaminases  2.5ULN and/or ULN < GGT  5ULN ].
[ GGN (gornja granica normale) < bilirubin  1,5GGN i/ili 1,5xGGN < transaminaze
1.6 %
(n=1008) 1,6
1.6 % in the Viramune prolonged-release group.
1,6 % u skupini na Viramuneu s produljenim oslobađanjem.
1.6 (1.4 to 1.79)
1,6 (1,4 do 1,79)
1.6 - 2.0 g/kg should be administered in divided doses over two to five days or 2.0 g/kg as a single dose.
Ukupnu dozu od 1,6 - 2,0 g/kg treba primijeniti u podijeljenim dozama kroz 2 do 5 dana ili jednokratno primijeniti dozu od 2,0 g/kg.
1.6 ml solution in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene).
1,6 ml otopine u ulošku (staklo tipa 1) s klipom (brombutil) i gumenim zatvaračem (brombutil/poliizopren).
1.6 mmHg).
1,6 mmHg).
1.6 – 2 g/kg bw or
1,6 - 2 g/kg TT ili
1.6% (-33.0% to 36.2%)
1,6% (-33,0% do 36,2%)
1.6% (2.5–2.9 mEq/l)
1,6% (2,5–2,9 mEq/l)
1.6-2 g/kg
1,6-2 g/kg
1.6-2 g/kg should be administered in divided doses over two to five days or 2.0 g/kg as a single dose.
1,6-2 g/kg mora se primijeniti u podijeljenim dozama tijekom dva do pet dana ili 2,0 g/kg u jednokratnoj dozi.
1.61 mg parathyroid hormone and 1.13 ml solvent (14 doses)
1,61 mg paratireoidnog hormona i 1,13 ml otapala (14 doza)
1.62 (1.32, 1.99) , P<0.0001
Vareniklin naspram NRT-a 1,74 (1,43, 2,10) , P<0,0001 1,62 (1,32, 1,99) , P<0,0001
1.68-foldc increase in likelihood
1,68-strukoc povećanje vjerojatnosti
1.7
HAQ
1.7 fold decrease
niženje za 1,7 puta
1.7 ml solution in a single use vial (type I glass) with stopper (fluoropolymer coated elastomeric) and seal (aluminium) with flip-off cap.
1,7 ml otopine u bočici za jednokratnu uporabu (staklo tip I) s čepom (elastomer obložen fluoropolimerom) i aluminijskim prstenom s „flip-off“ kapicom.
1.7 months (1.7, 1.7)
1,7 mjeseci (1,7; 1,7)
1.7 to 5.8% of the patients on perampanel in the clinical studies became seizure free during the 3 month maintenance period compared with 0% -1.0% on placebo.
U kliničkim je ispitivanjima 1,7% do 5,8% bolesnika na perampanelu prestalo imati napadaje tijekom 3 mjeseca terapije održavanja u usporedbi s 0%–1,0% bolesnika na placebu.
1.7 ± 0.4 mmol/l for sevelamer hydrochloride tablets).
1,6 ± 0,5 mmol/l kod primjene praška sevelamerkarbonata, odnosno 1,7 ± 0,4 mmol/l kod primjene tableta sevelamerklorida).
1.7% (0.5 to 4.2)
1,7% (0,5 do 4,2)
1.70 to 2.60
1,70 do 2,60
1.70a (1.22, 2.38)
1,70a (1,22; 2,38)
1.72 p = 0.0062
1,72 p < 0,0062
1.72 p = 0.0062
1,72 p<0,0062
1.72 to 2.74
1,72 do 2,74
1.74 (1.41, 2.14) , P<0.0001
2,26 (1,80, 2,85) , P<0,0001 1,87 (1,46, 2,39) , P<0,0001
1.74 (1.43, 2.10) , P<0.0001
1,77 (1,46, 2,14) , P<0,0001 1,74 (1,41, 2,14) , P<0,0001
1.76 – 2.42 mmol/L (5.5-7.5 mg/dl)
1,76 – 2,42 mmol/l (5,5-7,5 mg/dl)
1.77 (1.46, 2.14) , P<0.0001
4,00 (3,20, 5,00), P<0,0001 3,24 (2,56, 4,11) , P<0,0001
1.78 to 2.65
1,78 do 2,65
1.78 – 2.42 mmol/L (5.5 – 7.5 mg/dl)
1,78 – 2,42 mmol/l (5,5 – 7,5 mg/dl)
1.8 mg Daily
Liraglutid 1,8 mg na dan
1.8 mg/ml methyl parahydroxybenzoate (E218)
1,8 mg/ml metil-parahidroksibenzoata (E218)
1.8 mL
1,8 mL
1.8 ml
upotrijebiti
1.8 ml containing 0.90 mg fentanyl ensuring the delivery of 10 doses of 50 micrograms
1,8 ml sadrži 0,90 mg fentanila i osigurava unos 10 doza od 50 mikrograma.
1.8 ml containing 1.80 mg fentanyl ensuring the delivery of 10 doses of 100 micrograms
1,8 ml sadrži 1,80 mg fentanila i osigurava unos 10 doza od 100 mikrograma.
1.8 ml containing 3.60 mg fentanyl ensuring the delivery of 10 doses of 200 micrograms
1,8 ml sadrži 3,60 mg fentanila i osigurava unos 10 doza od 200 mikrograma.
1.8 ml of the diluent provided contains 358 mg ethanol (anhydrous) For the full list of excipients, see section 6.1.
Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
1.8 ml once daily
1,8 ml jednom dnevno
1.8 ml twice daily
1,8 ml dvaput dnevno
1.85 (1.58-2.18)
uzimanja fluvastatina i pitavastatina tijekom
1.87 months (95% CI 1.77-3.15 months.
1,87 mjeseci (95% CI: 1,77-3,15 mjeseci).
1.87-foldc increase in likelihood
1,87-strukoc povećanje
1.87-foldc increase in likelihood
1,87-strukoc povećanje vjerojatnosti
1.875 µg HA and half the amount of AS03 adjuvant) at 0 and 21 days in children aged 3 to 9 years.
1,875 µg HA i pola količine adjuvansa AS03) primijenjenih na 0. i 21. dan.
1.875 µg HA and half the amount of AS03 adjuvant) at 0 and 21 days in children aged 3 to 9 years.
1,875 µg hemaglutinina i pola količine adjuvansa AS03) na 0. i 21. dan u djece u dobi od 3 do 9 godina.
1.875 µg HA and half the amount of AS03 adjuvant) at 0 and 21 days in children aged 3 to 9 years.
1,875 µg hemaglutinina i pola količine adjuvansa AS03), na 0. i 21. dan u djece u dobi od 3 do 9 godina.
1.9 (P=0.0213)
1,9 (P = 0,0213)
1.9 fold decrease
niženje za 1,9 puta
1.9% (1 subject)
1,9% (1 pacijent)
1.92 to 2.43
1,92 do 2,43
1.94
paritaprevir
1.98 to 2.64
1,98 do 2,64
1.99 to 2.44
1,99 do 2,44
1.least squares mean (95% confidence interval)
1srednja vrijednost najmanjih kvadrata (95% interval pouzdanosti)
1/ REMOVE NEEDLE CAP 2/ HOLD MICRO-INJECTION SYSTEM
1/ UKLONITE ZATVARAČ IGLE
1/1
(HDPE)
1/1
(LDPE)
1/1
primjena
1/1
Proveblue
1/1
tableta
1/10 x 2,500, 5,000, 10,000, 20,000 doses
1/10 x 2500, 5000, 10000, 20000 doza
1/3
tableta
10
Često
10 (1 x 10) vial (multipack)
10 (1 x 10) bočica (višestruko pakiranje)
10 (10x1) bags (multipack)
10 (10x1) vrećica (višestruko pakiranje)
10 (10x1) bottles (multipack)
10 (10x1) bočica (višestruko pakiranje)
10 (10x1) pre-filled syringe (multipack)
10 (10 x1) unaprijed napunjena štrcaljki (višestruko pakovanje)
10 (2 packs of 5) pre- filled pens (multipack)
10 (2 pakovanja od 5) napunjenih brizgalica (višestruko pakovanje)
10 (2 x 5 ) cartridges (multipack)
10 (2 x 5) uložaka (višestruko pakiranje)
10 (2 x 5 ) pre- filled pens (multipack)
10 (2 x 5) napunjenih brizgalica (višestruko pakiranje)
10 (2 x 5) cartridges (multipack)
10 (2 x 5) uložaka (višestruko pakiranje)
10 (2 x 5) pre- filled pens (multipack)
10 (2 x 5) napunjenih brizgalica (višestruko pakiranje)
10 (2 x 5) pre- filled pens (multipack)
10 (2 x 5) napunjenih brizgalica (višestruko pakovanje)
10 (2x5) pre- filled pens (multipack)
10 (2 x 5) napunjenih brizgalica (višestruko pakiranje)
10 (2x5) pre-filled pens (multipack)
10 (2 x 5) napunjenih brizgalica (višestruko pakiranje)
10 12 mg/kg bodyweight/day
10 - 12 mg/kg tjelesne mase/danu
10 A-6250 Kundl Austria
10 A-6250 Kundl Austrija
10 ampoules: solvent
10 ampula: otapalo
10 and 20 ml bottle
Bočica od 10 ml i 20 ml
10 applicators
10 aplikatora
10 av. de La Ballastière 33500 Libourne FRANCE
10 av. de La Ballastière 33500 Libourne FRANCUSKA
10 bags +
10 vrećica +
10 bottle
10 boca
10 bottles
10 boca
10 bottles
10 bočica
10 bottles
Pakovanje
10 bottles of 100 doses (10 x 100 ml)
10 bočica od 100 doza (10 x 100 ml).
10 capsules (750 mg)
10 kapsula
10 capsules + 1 inhaler 30 capsules + 1 inhaler
10 kapsula + 1 inhalator 30 kapsula + 1 inhalator
10 cartridges
10 uložaka
10 cartridges of 3 mL
10 uložaka od 3 ml
10 cartridges of 3ml.
10 uložaka od 3 ml.
10 cups
10 čašica
10 dispersible tablets
10 tableta za oralnu suspenziju
10 dispersible tablets 30 dispersible tablets 100 dispersible tablets
10 tableta za oralnu suspenziju 30 tableta za oralnu suspenziju 100 tableta za oralnu suspenziju
10 doses
10 doza:
10 doses (0.5 ml)
10 doza (0,5 ml)
10 doses (10 ml)
10 doza (10 ml).
10 doses (20 ml).
10 doza (20 ml)
10 doses (5 ml).
10 doza (5 ml).
10 doses of vaccine (5 ml)
10 doza cjepiva (5 ml)
10 doses.
10 doza
10 doses: powder (10 bottles) + solvent (10 bottles) 50 doses: powder (50 bottles) + solvent (50 bottles)
10 doza: prah (10 bočica) + otapalo (10 bočica) 50 doza: prah (50 bočica) + otapalo (50 bočica)
10 film-coated tablets
10 filmom obložena tableta
10 film-coated tablets
10 filmom obloženih tableta 14 filmom obloženih tableta
10 film-coated tablets (PA/Alu/PVC/Alu) 30 film-coated tablets (PA/Alu/PVC/Alu) 60 film-coated tablets (PA/Alu/PVC/Alu) 120 film-coated tablets (PA/Alu/PVC/Alu) 180 film-coated tablets (PA/Alu/PVC/Alu) 360 film-coated tablets (PA/Alu/PVC/Alu) 10 film-coated tablets (PCTFE/PVC/Alu) 30 film-coated tablets (PCTFE/PVC/Alu) 60 film-coated tablets (PCTFE/PVC/Alu) 120 film-coated tablets (PCTFE/PVC/Alu) 180 film-coated tablets (PCTFE/PVC/Alu) 360 film-coated tablets (PCTFE/PVC/Alu)
10 filmom obloženih tableta (PA/Alu/PVC/Alu) 30 filmom obloženih tableta (PA/Alu/PVC/Alu) 60 filmom obloženih tableta (PA/Alu/PVC/Alu) 120 filmom obloženih tableta (PA/Alu/PVC/Alu) 180 filmom obloženih tableta (PA/Alu/PVC/Alu) 360 filmom obloženih tableta (PA/Alu/PVC/Alu) 10 filmom obloženih tableta (PCTFE/PVC/Alu) 30 filmom obloženih tableta (PCTFE/PVC/Alu) 60 filmom obloženih tableta (PCTFE/PVC/Alu) 120 filmom obloženih tableta (PCTFE/PVC/Alu) 180 filmom obloženih tableta (PCTFE/PVC/Alu) 360 filmom obloženih tableta (PCTFE/PVC/Alu)
10 film-coated tablets 14 film-coated tablets 20 film-coated tablets 100 film-coated tablets
10 filmom obloženih tableta 14 filmom obloženih tableta 20 filmom obloženih tableta 100 filmom obloženih tableta
10 G TUBE
TUBA OD 10 G
10 g valnemulin base per 100 g
10 g baze valnemulina po 100 g
10 g x 1 tube
10 g x 1 tuba
10 glass containers: powder 10 oral applicators: solvent 10 transfer adapters
10 staklenih spremnika: prašak 10 oralnih aplikatora: otapalo 10 nastavaka za prijenos
10 hours after, a dose of the H2-
najmanje 10 sati nakon njegove
10 hours from the time of calibration.
10 sati od sata kalibriranja.
10 In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups.
10 U kliničkim ispitivanjima pioglitazona, povišenje ALT-a više od tri puta iznad gornje granice normale bilo je jednako često kao uz placebo, ali manje često nego u skupinama koje su kao komparator primale metformin ili sulfonilureju.
10 injection needles
10 igle za injekcije
10 intermediate packs (1 pre-filled syringe)
10 međupakovanj a (1 napunjena štrcaljka)
10 kg to 15 kg
10 kg do15 kg
10 kg to < 15 kg N=5
10 kg do < 15 kg n=5
10 kg to less than 12 kg
10 kg do manje od 12 kg
10 kg to less than 12 kg
od 10 kg do manje od 12 kg
10 litres gas cylinder
Spremnik s plinom od 10 litara
10 litres would be needed for 1,000 10-day old chickens.
10 litara će biti potrebno za 1.000 pilića starih 10 dana.
10 mcg/kg
10 g/kg
10 mg
tablete
10 mg and 6.8/5.4 mmHg with placebo in a population of patients with mean baseline blood pressure of 157.3/99.7 mmHg.
13,8 mmHg s amlodipinom 10 mg te 6,8 mmHg odnosno 5,4 mmHg s placebom, u populaciji bolesnika s početnom srednjom vrijednošću krvnog tlaka od 157,3 mmHg odnosno 99,7 mmHg.
10 mg emodepside, 50 mg praziquantel.
10 mg emodepsid, 50 mg prazikvantel.
10 mg eow
10 mg svaki drugi tjedan
10 mg every 72 hours.
mg svaka 72 sata.
10 mg film-coated tablets: Each film-coated tablet contains 0.95 mg lactose monohydrate.
Filmom obložene tablete od 10 mg: Jedna filmom obložena tableta sadrži 0,95 mg laktoze hidrata.
10 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc.
10 mg filmom obložene tablete: poli(vinilni) alkohol, titanijev dioksid (E171), makrogol 3350, talk
10 mg fondaparinux sodium in 0.8 ml solution for injection
10 mg fondaparinuksnatrija u 0,8 ml otopine za injekcije
10 mg olanzapine per vial
10 mg olanzapina po bočici
10 mg once
10 mg
10 mg once daily for 4 days
10 mg jednom dnevno tijekom 4 dana
10 mg once daily on days 1-21 every 28 days
10 mg jednom dnevno od 1. do 21. dana svakih 28 dana
10 mg once daily on days 1-21, every 28 days
10 mg jednom dnevno od 1. do 21. dana, svakih 28 dana
10 mg orally once daily
10 mg peroralno jedanput na dan
10 mg orally once dailya
10 mg peroralno jedanput na
10 mg tablet
tableta od 10 mg
10 mg tablets: Robenacoxib 10 mg
10 mg tablete: robenakoksib 10 mg
10 mg terbinafine, 10 mg florfenicol, 1 mg betamethasone acetate
10 mg terbinafina, 10 mg florfenikola, 1 mg betametazon acetata
10 mg twice daily
10 mg dva puta na dan
10 mg twice daily for the first 7 days
10 mg dvaput na dan tijekom prvih 7 dana
10 mg/24 h may be reached by combination of a 6 mg/24 h and a 4 mg/24 h patch.
10 mg/24 h može se postići kombinacijom flastera s dozom 6 mg/24 h i 4 mg/24 h.
10 mg/80 mg chewable tablets
10 mg/80 mg tableta za žvakanje
10 mg/day N=94
10 mg/dan N=94
10 mg/day N=95
10 mg/dan N=95
10 mg/kg
10 mg/kg svakih
10 mg/kg every 24 hours
10 mg/kg svakih 24 sata
10 mg/kg infliximab group (18/242 or 7.4% [p=0.011]) than in the placebo group (36/244; 14.8%).
5 mg/kg (28/242 ili 11, 6% [N.S.]) i 10 mg/kg (18/242 ili 7,4% [p = 0, 011]) nego onih koji su primali placebo (36/244; 14,8%).
10 mg/kg once every 24 hours
10 mg/kg jedanput svaka 24 sata
10 mg/kg once every 24 hours infused over 60 minutes
10 mg/kg jedanput svaka 24 sata infuzijom tijekom 60 minuta
10 mg/kg twice daily
10 mg/kg dva puta na dan
10 mg/kg) should be used due to the dose-dependent penetration of micafungin into the CNS (see section 5.2).
10 mg/kg) zbog penetracije mikafungina u SŽS ovisne o dozi (vidjeti dio 5.2).
10 mg/kg/day ( 4 times the exposure with the MRHD based on AUC).
10 mg/kg/dan ( 4 puta izloženost s maksimalno dozvoljenom dozom kod ljudi temeljena na AUC).
10 mg/ml after first dilution.
10 mg/ml nakon prvog razrjeđenja.
10 mg/ml solution for injection/infusion is packed in 6 ml nominal capacity glass vials (type I) with siliconized bromobutyl rubber stoppers and sealed with an aluminium/polypropylene tear off cap.
Otopina za injekciju/infuziju od 10 mg/ml pakirana je u staklene bočice (staklo tipa I) deklariranog volumena 6 ml s čepovima od silikonizirane brombutilne gume i aluminijskim/polipropilenskim zaštitnim zatvaračem koji se otkida.
10 mg: Round and pink, marked with "A" over "640" on one side and "10" on the other.
10 mg: Okrugla i ružičasta s oznakom "A" iznad "640" na jednoj strani i "10" na drugoj.
10 microgram
10 mikrograma
10 micrograms Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.50 milligram Al+)
10 mikrograma Adsorbiran na amorfni aluminijev hidroksifosfat sulfat (0,50 miligrama Al+)
10 milligrams (mg) for every kilogram (kg) of body weight, given once a day.
10 miligrama (mg) po svakom kilogramu (kg) tjelesne težine, jednom dnevno.
10 million IU/mL
5 milijuna IU/0,5 ml
10 million IU/mL solution for injection or infusion 1 single dose vial
10 milijuna IU/ ml otopina za injekciju ili infuziju 1 jednodozna bočica
10 ml
(staklena)
10 ml
Otapalo: 10 ml
10 ml
Potkožno
10 ml
približno 10 ml
10 ml (10 doses)
10 ml (10 doza)
10 ml (10 doses) 50 ml (50 doses) 100 ml (100 doses) 250 ml (250 doses)
10 ml (10 doza) 50 ml (50 doza) 100 ml (100 doza) 250 ml (250 doza)
10 ml (10 doses).
10 mL ( 10 doza )
10 ml (10 doses).
10 ml (10 doza ).
10 ml (after reconstitution)
10 ml (nakon rekonstitucije)
10 ml (two 5 ml vials)
10 ml (dvije bočice od 5 ml)
10 ml bottle
10 ml u bočici
10 ml bottle
Bočice od 10 ml
10 ml clear glass Type I vial with a bromobutyl rubber stopper and aluminium seal and a plastic flip- off cap containing 4 ml of concentrate for solution for infusion.
Prozirna staklena bočica od 10 ml (staklo tip I) s 4 ml koncentrata za otopinu za infuziju, bromobutilnim gumenim čepom i aluminijskim prstenom te plastičnim "flip-off" zatvaračem.
10 ml clear, colourless Type-I glass vial, closed with flurotec rubber stopper and a orange flip-off aluminium over seal containing 9 ml of concentrate.
Prozirna bezbojna staklena bočica od 10 ml (staklo tip I) s 9 ml koncentrata, zatvorena gumenim (flurotec) čepom i narančastim “flip-off” aluminijskim zaštitnim zatvaračem.
10 ml glass vial containing either 3ml or 6 ml 50 µl pump 20 ml glass vial containing either 3ml or 11ml 100µl pump 50 ml glass vial containing either 8 ml or 33 ml 215µl pump
u staklenoj bočici od 10 ml sadrži 3 ml ili 6 ml pumpica od 50 µl u staklenoj bočici od 20 ml sadrži 3 ml ili 11 ml pumpica od 100 µl u staklenoj bočici od 50 ml sadrži 8 ml ili 33 ml pumpica od 215 µl
10 ml glass vial containing either 3ml or 6 ml 50 µl pump 20 ml glass vial containing either 3ml or 11ml 100µl pump 50 ml glass vial containing either 8 ml or 33 ml 215µl pump Not all pack sizes may be marketed.
Staklena bočica od 10 ml sadrži 3 ml ili 6 ml pumpica od 50 µl Staklena bočica od 20 ml sadrži 3 ml ili 11 ml pumpica od 100 µl Staklena bočica od 50 ml sadrži 8 ml ili 33 ml pumpica od 215 µl Ne moraju sve veličine pakovanja biti u prometu.
10 ml LUER syringe),
10 ml LUER štrcaljka),
10 mL of concentrate in a clear type I glass vial closed by a poly(ethylene-co-tetrafluoroethylene)-coated butyl rubber stopper covered with a crimped-on aluminium ring and a plastic flip-off cap.
10 ml koncentrata u bočici od prozirnog stakla tipa I zatvorenoj čepom od butilne gume obložene poli(etilen-ko-tetrafluoroetilenom) pokrivenim aluminijskim prstenom i plastičnim poklopcem.
10 ml of solvent in a vial (type I glass) with a stopper (rubber) a disc (plastic) and a cap (aluminium).
10 ml otapala u bočici (staklo tipa I), s čepom (guma i bez lateksa), diskom (plastika) i kapicom (aluminij).
10 ml of solvent in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
10 ml otapala u bočici (staklo tipa I), s čepom (guma i bez lateksa), diskom (plastika) i kapicom (aluminij).
10 ml or 20 ml injection vial.
Injekcijska bočica od 10 ml ili 20 ml.
10 ml oral syringe with 1 ml increments (for single use): see figure below
Štrcaljka za usta od 10 ml s oznakama za doziranje u razmaku od 1 ml (za jednokratnu uporabu): vidjeti sliku ispod
10 ml oseltamivir suspension delivers 1.7 g of sorbitol.
10 ml oseltamivir suspenzije sadrži 1,7 g sorbitola.
10 ml plastic syringe pre-filled with 10 ml of water for injections for reconstitution.
Plastična štrcaljka od 10 ml napunjena sa 10 ml vode za injekcije za rekonstituciju.
10 ml plastic syringe pre-filled with 8 ml of water for injections for reconstitution.
Plastična štrcaljka od 10 ml napunjena sa 8 ml vode za injekcije za rekonstituciju.
10 ml presentation: amber glass bottle (type III) with polyethylene child resistant closure, polyethylene insert and an amber polypropylenedosing syringe.
Pakovanje od 10 ml: boca boje jantara (tip III) s polietilenskim čepom za zaštitu od otvaranja za djecu, polietilenskim umetkom i polipropilenskom štrcaljkom za doziranje boje jantara.